Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntingt...
Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington’s disease
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Currently, there are no therapies available to modify the disease progression of Huntington’s disease (HD). Recent clinical trial failures of antisense oligonucleotide candidates in HD have demonstrated the need for new therapeutic approaches. Here, we developed a novel in-silico fragment scanning approach across the surface of mutant huntingtin (m...
Alternative Titles
Full title
Fragment-based virtual screening identifies a first-in-class preclinical drug candidate for Huntington’s disease
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_e98c904096fc4a3d86ffffc25854d444
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_e98c904096fc4a3d86ffffc25854d444
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-022-21900-2
